methyl 2-(4-cyclopropylsulfonylphenyl)acetate | 1080059-87-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 2-(4-cyclopropylsulfonylphenyl)acetate
• 英文别名: methyl [4-(cyclopropylsulfonyl)phenyl]acetate
• CAS: 1080059-87-5
• 化学式: C₁₂H₁₄O₄S
• 分子量: 254.307
• InChiKey: IRJYAOUEENWPFA-UHFFFAOYSA-N

物化性质

• 沸点：
  416.7±37.0 °C(Predicted)
• 密度：
  1.315±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  68.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 2-(4-cyclopropylsulfonylphenyl)acetate 以98的产率得到methyl 2-bromo-2-(4-cyclopropylsulfonylphenyl)acetate
  参考文献：
  名称：

  European Journal of Medicinal Chemistry. 2017, 133, 268-286

  摘要：

  DOI：
• 作为产物：
  描述：

  2-(4-环丙基硫烷基苯基)乙酸 在 氯化亚砜 、 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 反应 5.0h， 生成 methyl 2-(4-cyclopropylsulfonylphenyl)acetate
  参考文献：
  名称：

  Discovery of liver-directed glucokinase activator having anti-hyperglycemic effect without hypoglycemia

  摘要：

  Glucokinase activators (GKAs) are among the emerging drug candidates for the treatment of type 2 diabetes (T2D). Despite effective blood glucose lowering in clinical trials, many pan-GKAs "acting both in pancreas and liver" have been discontinued from clinical development mainly because of their potential to cause hypoglycemia. Pan-GKAs over sensitize pancreatic GK, resulting in insulin secretion even at sub-normoglycemic level which might be a possible explanation for hypoglycemia. An alternative approach to minimize the risk of hypoglycemia is to use liver-directed GKAs, which are reported to be advancing well in clinical development. Here, we report the discovery and structure-activity relationship (SAR) studies on a novel 2-phenoxy-acetamide series with the aim of identifying a liver-directed GKA. Incorporation of a carboxylic acid moiety as an active hepatocyte uptake recognizing element at appropriate position of 2-phenoxy-acetamide core led to the identification of 26, a potent GKA with predominant liver-directed pharmacokinetics in mice. Compound 26 on oral administration significantly reduced blood glucose levels during an oral glucose tolerance test (oGTT) performed in diet-induced obese (DIO) mice, while showing no sign of hypoglycemia in normal C57 mice over a 10-fold dose range, even when dosed at fasted condition. Together, these data demonstrate a liver-directed GKA has beneficial effect on glucose homeostasis with reduced risk of hypoglycemia. (C) 2017 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2017.03.042

文献信息

• NITROGEN-CONTAINING FIVE-MEMBERED HETEROCYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2149550A1

  公开（公告）日：2010-02-03

  The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof. The compound of the present invention has a glucokinase activity, and is useful as a medicament such as an agent for the prophylaxis or treatment of diabetes, obesity and the like, and the like.

  本发明提供了一种由以下式（I）表示的化合物： 其中每个符号如规范中定义，或其盐。本发明的化合物具有葡萄糖激酶活性，并且可用作药物，如预防或治疗糖尿病、肥胖等的药剂，诸如此类。
• US8318746B2
  申请人：——

  公开号：US8318746B2

  公开（公告）日：2012-11-27